このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Evaxion Biotech マネジメント

マネジメント基準チェック /34

Evaxion Biotech'sの CEO はChristian Kanstrupで、 Sep2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 373.00Kで、 31.1%給与と68.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.36%を直接所有しており、その価値は$ 181.62K 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と3.1年です。

主要情報

Christian Kanstrup

最高経営責任者

US$373.0k

報酬総額

CEO給与比率	31.1%
CEO在任期間	less than a year
CEOの所有権	1.4%
経営陣の平均在職期間	3.7yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Mar 31

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Jun 03

CEO報酬分析

Evaxion Biotech の収益と比較して、Christian Kanstrup の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$373k	US$116k	-US$22m

報酬と市場: Christianの総報酬 ($USD 373.00K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Christianの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Christian Kanstrup (52 yo)

less than a year

在職期間

US$373,000

報酬

Mr. Christian Kanstrup, MSc, serves as Chief Executive Officer of Evaxion Biotech A/S since September 01, 2023. He joined Evaxion Biotech A/S on September 01, 2023. He previously served as Executive Vice P...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christian Kanstrup	Chief Executive Officer	less than a year	US$373.00k	1.36% $ 208.8k
Niels Moeller	Co-Founder	16.4yrs	US$58.00k	7.89% $ 1.2m
Andreas Mattsson	Co-Founder and Chief AI & Culture Officer	16.4yrs	US$246.00k	7.76% $ 1.2m
Jesper Nissen	Interim CFO & COO	2.3yrs	US$296.00k	0.068% $ 10.4k
Birgitte Rono	Chief Scientific Officer	2.8yrs	US$269.00k	0.068% $ 10.4k
Jürgen Langhärig	Head of Business Development & Member of Advisory Board	4.7yrs	データなし	データなし

3.7yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: EVAXの経営陣は経験豊富であると考えられます ( 3.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Niels Moeller	Co-Founder	2.1yrs	US$58.00k	7.89% $ 1.2m
Jürgen Langhärig	Head of Business Development & Member of Advisory Board	2.3yrs	データなし	データなし
Rajeev Surati	Member of Advisory Board	no data	データなし	データなし
Robert Palay	Member of Advisory Board	no data	データなし	データなし
Jeffrey Weber	Member of Advisory Board	no data	データなし	データなし
Soren Brunak	Member of Advisory Board	no data	データなし	データなし
Michael Washabaugh	Member of Advisory Board	no data	データなし	データなし
Lars Holtug	Independent Director	3.1yrs	US$64.00k	0.14% $ 20.9k
Anthony Purcell	Member of Advisory Board	no data	データなし	データなし
Andrew Webber	Member of Advisory Board	no data	データなし	データなし
Marianne Sogaard	Independent Chairwoman of the Board	3.6yrs	US$193.00k	1.51% $ 232.0k
Roberto Pineda	Independent Director	6.4yrs	US$68.00k	0.74% $ 114.2k

3.1yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: EVAXの取締役会は経験豊富であると考えられます ( 3.1年の平均在任期間)。

Evaxion Biotech マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Recent updates

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study

Evaxion Biotech A/S Enrolls First Patient in the Global Phase 2B Clinical Trial of EVX-01

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Forecast to breakeven in 2024

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target

Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer

Evaxion Biotech A/S announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2A Clinical Trial for EVX-02

Evaxion Biotech A/S, Annual General Meeting, May 03, 2022

Evaxion Biotech A/S Announces Executive Changes

Evaxion Biotech A/S Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine

Independent Director Helen Boudreau has left the company

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Evaxion Biotech A/S has completed an IPO in the amount of $30 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /34